UPEXI, INC.
For the period ended Jun 30, 2025. Filed Sep 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 24, 2025
UPXI$0.66+3.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| UPEXI, INC. | |||
|---|---|---|---|
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||
| Year Ended June 30, | |||
| 2025 · 2024 | |||
| Revenue | |||
| Revenue | $14,826,336 | $26,000,652 | |
| Digital asset revenue | 985,009 | - | |
| Total revenue | 15,811,345 | 26,000,652 | |
| Cost of revenue | 4,943,305 | 13,176,073 | |
| Gross profit | 10,868,040 | 12,824,579 | |
| Operating expenses | |||
| Sales and marketing | 4,001,094 | 5,989,727 | |
| Distribution costs | 4,691,964 | 8,611,702 | |
| General and administrative expenses | 11,935,582 | 6,771,937 | |
| Realized and unrealized (gain) loss on digital assets | (105,474) | - | |
| Share-based compensation | 2,356,862 | 1,169,843 | |
| Amortization of acquired intangible assets | 76,758 | 2,410,431 | |
| Depreciation | 681,000 | 1,268,355 | |
| Impairment of long-lived asset - building | - | 336,434 | |
| Loss on the sale / abandonment of assets in relocation | - | 569,195 | |
| Impairment of intangible assets and goodwill | - | 7,869,425 | |
| Lease impairment (gain on settlement), Delray Beach facility | (269,994) | 289,969 | |
| 23,367,792 | 35,287,018 | ||
| Loss from operations | (12,499,752) | (22,462,439) | |
| Other income (expense), net | |||
| Other | (10,743) | (16,443) | |
| Interest (expense) income, net | (1,173,714) | (3,124,723) | |
| Other income (expense), net | (1,184,457) | (3,141,166) | |
| Loss on operations before income tax | (13,684,209) | (25,603,605) | |
| Income tax benefit (expense) | - | 332,101 | |
| - | 332,101 | ||
| Net loss from continuing operations | (13,684,209) | (25,271,504) | |
| Gain (loss) from the sale of: | |||
| Interactive Offers | - | 237,670 | |
| VitaMedica | - | 1,948,538 | |
| E-Core | - | (1,737,326) | |
| - | 448,882 | ||
| Income (loss) on discontinued operations | |||
| Infusionz | 71,976 | ||
| Interactive offers | - | (187,003) | |
| VitaMedica | - | 213,636 | |
| E-core | - | 1,065,575 | |
| Income (loss) income from discontinued operations | - | 1,164,184 | |
| Net income (loss) attributable to Upexi, Inc. | $(13,684,209) | (23,658,438) | |
| Basic income (loss) per share: | |||
| Income (loss) per share from continuing operations | $(1.73) | $(24.60) | |
| (Loss) income per share from discontinued operations | $ | - | $1.13 |
| Total income (loss) per share attributable to Upexi shareholders | $(1.73) | $(23.03) | |
| Diluted income (loss) per share: | |||
| Income (loss) per share from continuing operations | $(1.73) | $(24.60) | |
| (Loss) income per share from discontinued operations | $ | - | $1.13 |
| Total income (loss) per share attributable to Upexi shareholders | $(1.73) | $(23.03) | |
| Basic weighted average shares outstanding | 7,914,268 | 1,027,232 | |
| Fully diluted weighted average shares outstanding | 7,914,268 | 1,027,232 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.